enabling researchers to make meaningful advances in their fields. Promega invites attendees of SFN 2024 to Booth #1316 to experience live demonstrations of the Glomax® Galaxy, showcasing its potential to transform research. About Promega...
in Tempe, Arizona, BioCare, Inc. has been devoted to delivering specialty and therapeutic biological products since 1982. For more information, visit www.BioCare
to accelerate production of vaccine-relevant proteins for use in clinical trials. This project fully aligns with the 100 Days Mission spearheaded by CEPI. The project extension follows a successful first six months during which LenioBio achieved...
international standards of excellence in training and was awarded following a comprehensive audit under the ANSI/ASTM E2659-18 standard. This validates that ISCT's training programs are built on robust quality management systems, thorough learner...
Treatment of Metastatic Tumors Harboring an Ataxia-Telangiectasia Mutated (ATM) Mutation.” “These encouraging early Phase 1 data build further support for the broad clinical potential of camonsertib,” said Maria Koehler, MD, PhD, Executive Vice...
stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like...
medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 receptors “Today’s landmark approval of our first-in-class treatment for...
diseases announced that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in Hepatology. Previously, Galmed reported results from the...
Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EYD-001, its highly selective and potent, orally bioavailable TAK1 inhibitor for the treatment of systemic sclerosis. EydisBio is an...
oral testosterone treatment for men. Together, they aim to conduct a pioneering study that will measure the impact of GLP-1s on muscle mass in male patients using the treatment for weight loss. In conjunction with muscle mass reduction being a...
and prevention of cancer, announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by a grant from the U.S. Department of Defense. The proposed Phase 2 trial...
due to its large body of clinical evidence, well-established mechanism of action (MOA) and high patient satisfaction.1,2,3 Built on a legacy of proven, natural-looking outcomes, Ultherapy PRIME redefines the future of non-invasive skin lifting and...
market and beyond. This acquisition enables MECOTEC to manufacture and supply Restore's signature cryo-chamber models—the 1Cool, 2Cool, and 4Cool—exclusively to Restore locations in the United States, while also offering these designs to MECOTEC's...
At Fakuma, Netstal will be producing 10 ml syringe barrels with Luer-Lock adapters made of COC using an all-electric Elion MED with a clamping force of 1750 kN.The part weight is 7.8 g and the cycle time is around 20 seconds. Netstal processes a...
many rare and genetic kidney diseases including IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS) and APOL1-mediated kidney disease (AMKD). Members connect with each other to learn about policy issues impacting kidney care, receive...
Since the residence time of the drug particles in the stomach (~2-3 hours) is much shorter than the usual dosing interval (~12-24 hours), the blood concentration of such drugs fluctuates significantly with repeated intake. This is not...
C. Mary, MD, Founder and Medical Director of The Remedy Room in New Orleans said, “We have utilized NAD IV therapy for 11 years and are excited to introduce Niagen IV in partnership with ChromaDex, a cutting-edge advancement. With Niagen IV, our...
range of solutions with cytotoxic, supportive & targeted drugs. The group employs over 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality...
pharmaceutical company developing proprietary cannabinoid therapeutics, announced that the first patient has received BRC-001, an experimental supportive care therapy for breast cancer patients. City of Hope researchers are evaluating whether this...
raw materials business in its newly released 2024 mid-year financial report. The company reported a total revenue of RMB 2.811 billion (～ USD 393.54 million) for the first half of the year, with a net profit of RMB 342 million (～ USD 47.88 million)...
